2026 Q2 -tulosraportti
Äänite tulossa
Tänään
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 30.7. | ||
2026 Q1 -tulosraportti 22.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·17 t sittenPoor report today and they also lower their forecast. I was fooled when I participated in the share issue. They promised the moon but it turned out to be a flop now.
Is there no reason for J&J to build up inventory costs in advance? Seems risk-free from their side? Can additional orders come continuously?- ·1 päivä sittenI think it will take another quarter before it starts showing in the accounting? Report tomorrow...
·6.7.We resume coverage of Ortoma with a fair value range of 16–22 SEK per share after previously having withdrawn our analysis due to our role in the recent new share issues. Last week, Ortoma announced a large order from its partner DePuy Synthes. In our view, the order significantly improves visibility in the commercial rollout of OTS Hip in key markets and provides an early indication of the expected sales growth. Despite the recent recovery in the share price, the stock is still down year-to-date. We believe this primarily reflects financing-related pressure following the recent capital raises, along with continued weakness in the Swedish small-cap medtech sector. As the commercial launch approaches, we see room for increased investor interest and improved sentiment, with focus shifting back to commercial execution and the pace of market adoption. The large order underscores commercial progress. Last week, Ortoma announced an order for 44 OTS Hip systems, along with related items and licenses, from its partner DePuy Synthes. The 32 MSEK order covers Europe, USA, and Japan, with deliveries planned for H2 2026, with a focus towards Q4. In our view, the order represents an important commercial milestone and strengthens our conviction that the rollout of OTS Hip is approaching its commercial launch, with Europe expected to lead, followed by the USA. Ready for a strong second half. We expect a relatively weak Q2, as the quarter constitutes a transition period characterized by extensive market preparations. However, the latest order strengthens our confidence that sales will accelerate significantly in the second half, driven by the broader commercial rollout of OTS Hip. Despite the positive order intake, we maintain a cautious view on sales for 2026e, as we await further clarity regarding the rollout in Europe and the USA. We resume coverage of Ortoma with a fair value range of 16–22 SEK per share.The forecast of 150 systems seems to have been more related to the new share issue? They will have to wait for upcoming orders.- ·19.6.The next report will be extra exciting here, is it taking time to ramp up sales? Don't see any press releases/marketing from J&J yet etc?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
Äänite tulossa
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sittenPoor report today and they also lower their forecast. I was fooled when I participated in the share issue. They promised the moon but it turned out to be a flop now.Is there no reason for J&J to build up inventory costs in advance? Seems risk-free from their side? Can additional orders come continuously?
- ·1 päivä sittenI think it will take another quarter before it starts showing in the accounting? Report tomorrow...
- ·6.7.We resume coverage of Ortoma with a fair value range of 16–22 SEK per share after previously having withdrawn our analysis due to our role in the recent new share issues. Last week, Ortoma announced a large order from its partner DePuy Synthes. In our view, the order significantly improves visibility in the commercial rollout of OTS Hip in key markets and provides an early indication of the expected sales growth. Despite the recent recovery in the share price, the stock is still down year-to-date. We believe this primarily reflects financing-related pressure following the recent capital raises, along with continued weakness in the Swedish small-cap medtech sector. As the commercial launch approaches, we see room for increased investor interest and improved sentiment, with focus shifting back to commercial execution and the pace of market adoption. The large order underscores commercial progress. Last week, Ortoma announced an order for 44 OTS Hip systems, along with related items and licenses, from its partner DePuy Synthes. The 32 MSEK order covers Europe, USA, and Japan, with deliveries planned for H2 2026, with a focus towards Q4. In our view, the order represents an important commercial milestone and strengthens our conviction that the rollout of OTS Hip is approaching its commercial launch, with Europe expected to lead, followed by the USA. Ready for a strong second half. We expect a relatively weak Q2, as the quarter constitutes a transition period characterized by extensive market preparations. However, the latest order strengthens our confidence that sales will accelerate significantly in the second half, driven by the broader commercial rollout of OTS Hip. Despite the positive order intake, we maintain a cautious view on sales for 2026e, as we await further clarity regarding the rollout in Europe and the USA. We resume coverage of Ortoma with a fair value range of 16–22 SEK per share.The forecast of 150 systems seems to have been more related to the new share issue? They will have to wait for upcoming orders.
- ·19.6.The next report will be extra exciting here, is it taking time to ramp up sales? Don't see any press releases/marketing from J&J yet etc?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 30.7. | ||
2026 Q1 -tulosraportti 22.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
2026 Q2 -tulosraportti
Äänite tulossa
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 30.7. | ||
2026 Q1 -tulosraportti 22.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sittenPoor report today and they also lower their forecast. I was fooled when I participated in the share issue. They promised the moon but it turned out to be a flop now.Is there no reason for J&J to build up inventory costs in advance? Seems risk-free from their side? Can additional orders come continuously?
- ·1 päivä sittenI think it will take another quarter before it starts showing in the accounting? Report tomorrow...
- ·6.7.We resume coverage of Ortoma with a fair value range of 16–22 SEK per share after previously having withdrawn our analysis due to our role in the recent new share issues. Last week, Ortoma announced a large order from its partner DePuy Synthes. In our view, the order significantly improves visibility in the commercial rollout of OTS Hip in key markets and provides an early indication of the expected sales growth. Despite the recent recovery in the share price, the stock is still down year-to-date. We believe this primarily reflects financing-related pressure following the recent capital raises, along with continued weakness in the Swedish small-cap medtech sector. As the commercial launch approaches, we see room for increased investor interest and improved sentiment, with focus shifting back to commercial execution and the pace of market adoption. The large order underscores commercial progress. Last week, Ortoma announced an order for 44 OTS Hip systems, along with related items and licenses, from its partner DePuy Synthes. The 32 MSEK order covers Europe, USA, and Japan, with deliveries planned for H2 2026, with a focus towards Q4. In our view, the order represents an important commercial milestone and strengthens our conviction that the rollout of OTS Hip is approaching its commercial launch, with Europe expected to lead, followed by the USA. Ready for a strong second half. We expect a relatively weak Q2, as the quarter constitutes a transition period characterized by extensive market preparations. However, the latest order strengthens our confidence that sales will accelerate significantly in the second half, driven by the broader commercial rollout of OTS Hip. Despite the positive order intake, we maintain a cautious view on sales for 2026e, as we await further clarity regarding the rollout in Europe and the USA. We resume coverage of Ortoma with a fair value range of 16–22 SEK per share.The forecast of 150 systems seems to have been more related to the new share issue? They will have to wait for upcoming orders.
- ·19.6.The next report will be extra exciting here, is it taking time to ramp up sales? Don't see any press releases/marketing from J&J yet etc?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt